Mesoblast Advances Stem-Cell Drugs As Catalysts Approach
This article was originally published in The Pink Sheet Daily
Australian regenerative medicines company Mesoblast is working with its partner Teva to move a stem-cell treatment for congestive heart failure into Phase III clinical studies.
You may also be interested in...
A day after announcing the abrupt resignation of CEO Jeremy Levin, Teva’s management emphasized that the company’s current strategy would continue, including plans for dealing with ongoing pressures from Copaxone’s loss of exclusivity, and under-performance of the European generics businesses. Teva hoped to persuade rattled investors of its steady road to growth.
Belgian biotech Cardio3 BioSciences is in a leading position in the race to develop a stem cell-based therapy for severe heart failure.
Australian Stem Cell Company Mesoblast To Get AU$170 Million Private Placement As Clinical Trials Ramp Up
Mesoblast Ltd., which Teva holds a 20% stake in, aims to raise AU$170 million by issuing new shares to a select group of existing and new global institutional investors.